Novel research strategies in the pharmacology of schizophrenia

Barbara K. Lipska, Daniel Weinberger

Research output: Contribution to journalArticle

Abstract

Currently available drugs to treat schizophrenia prove to be only partially effective and often produce disturbing side effects. Because pathophysiological mechanisms underlying schizophrenia are unclear, and animal models with construct validity virtually do not exist, pharmaceutical research faces considerable difficulties in its attempt to develop more effective drugs to treat this disorder. Recent findings reviewed in this article about differences in the mode of action between typical and atypical neuroleptic drugs may provide some clues about the disease itself and about potential new therapies. The discovery of novel dopamine receptor subtypes as potential targets for the antipsychotic action may offer new possibilities for pharmaceutical industry. Glutamatergic AMPA receptors seem to be another important potential site of action for novel antischizophrenic drugs, in particular those targeting negative symptoms. Findings from studies on the effects of chronic treatment wlth typical and atypical drugs on postreceptor intracellular processes, such as expression of genes encoding transcription factors or their target genes, may elucidate mechanisms by which these drugs exert their therapeutic action. Finally, novel animal models with construct and predictive validity, which address neurodevelopmental aspects of the disorder, may bring us better understanding of the human disease and offer a novel strategy to explore unconventional treatment.

Original languageEnglish (US)
Pages (from-to)103-113
Number of pages11
JournalDrugs of Today
Volume33
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Schizophrenia
Pharmacology
Research
Pharmaceutical Preparations
Antipsychotic Agents
Animal Models
AMPA Receptors
Dopamine Receptors
Drug Industry
Action Potentials
Transcription Factors
Gene Expression
Therapeutics
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Novel research strategies in the pharmacology of schizophrenia. / Lipska, Barbara K.; Weinberger, Daniel.

In: Drugs of Today, Vol. 33, No. 2, 1997, p. 103-113.

Research output: Contribution to journalArticle

Lipska, Barbara K. ; Weinberger, Daniel. / Novel research strategies in the pharmacology of schizophrenia. In: Drugs of Today. 1997 ; Vol. 33, No. 2. pp. 103-113.
@article{de06f49d1d304b48b6f714ae98e778cf,
title = "Novel research strategies in the pharmacology of schizophrenia",
abstract = "Currently available drugs to treat schizophrenia prove to be only partially effective and often produce disturbing side effects. Because pathophysiological mechanisms underlying schizophrenia are unclear, and animal models with construct validity virtually do not exist, pharmaceutical research faces considerable difficulties in its attempt to develop more effective drugs to treat this disorder. Recent findings reviewed in this article about differences in the mode of action between typical and atypical neuroleptic drugs may provide some clues about the disease itself and about potential new therapies. The discovery of novel dopamine receptor subtypes as potential targets for the antipsychotic action may offer new possibilities for pharmaceutical industry. Glutamatergic AMPA receptors seem to be another important potential site of action for novel antischizophrenic drugs, in particular those targeting negative symptoms. Findings from studies on the effects of chronic treatment wlth typical and atypical drugs on postreceptor intracellular processes, such as expression of genes encoding transcription factors or their target genes, may elucidate mechanisms by which these drugs exert their therapeutic action. Finally, novel animal models with construct and predictive validity, which address neurodevelopmental aspects of the disorder, may bring us better understanding of the human disease and offer a novel strategy to explore unconventional treatment.",
author = "Lipska, {Barbara K.} and Daniel Weinberger",
year = "1997",
language = "English (US)",
volume = "33",
pages = "103--113",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Novel research strategies in the pharmacology of schizophrenia

AU - Lipska, Barbara K.

AU - Weinberger, Daniel

PY - 1997

Y1 - 1997

N2 - Currently available drugs to treat schizophrenia prove to be only partially effective and often produce disturbing side effects. Because pathophysiological mechanisms underlying schizophrenia are unclear, and animal models with construct validity virtually do not exist, pharmaceutical research faces considerable difficulties in its attempt to develop more effective drugs to treat this disorder. Recent findings reviewed in this article about differences in the mode of action between typical and atypical neuroleptic drugs may provide some clues about the disease itself and about potential new therapies. The discovery of novel dopamine receptor subtypes as potential targets for the antipsychotic action may offer new possibilities for pharmaceutical industry. Glutamatergic AMPA receptors seem to be another important potential site of action for novel antischizophrenic drugs, in particular those targeting negative symptoms. Findings from studies on the effects of chronic treatment wlth typical and atypical drugs on postreceptor intracellular processes, such as expression of genes encoding transcription factors or their target genes, may elucidate mechanisms by which these drugs exert their therapeutic action. Finally, novel animal models with construct and predictive validity, which address neurodevelopmental aspects of the disorder, may bring us better understanding of the human disease and offer a novel strategy to explore unconventional treatment.

AB - Currently available drugs to treat schizophrenia prove to be only partially effective and often produce disturbing side effects. Because pathophysiological mechanisms underlying schizophrenia are unclear, and animal models with construct validity virtually do not exist, pharmaceutical research faces considerable difficulties in its attempt to develop more effective drugs to treat this disorder. Recent findings reviewed in this article about differences in the mode of action between typical and atypical neuroleptic drugs may provide some clues about the disease itself and about potential new therapies. The discovery of novel dopamine receptor subtypes as potential targets for the antipsychotic action may offer new possibilities for pharmaceutical industry. Glutamatergic AMPA receptors seem to be another important potential site of action for novel antischizophrenic drugs, in particular those targeting negative symptoms. Findings from studies on the effects of chronic treatment wlth typical and atypical drugs on postreceptor intracellular processes, such as expression of genes encoding transcription factors or their target genes, may elucidate mechanisms by which these drugs exert their therapeutic action. Finally, novel animal models with construct and predictive validity, which address neurodevelopmental aspects of the disorder, may bring us better understanding of the human disease and offer a novel strategy to explore unconventional treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030911151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030911151&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 103

EP - 113

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2

ER -